TNT EsophagusNCT07603375
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
At risk: Primary completion moved 51 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Primary completion pushed from Aug 1, 2029 to Sep 21, 2029
- Start date changed from estimate of Sep 2026 to Oct 21, 2026
- Study completion date: Feb 2034 to Mar 21, 2034
- Notable Recruitment opened
- Eligibility criteria expanded, about 21 words
- Secondary endpoints: details revised at 8 of 10 entries
- Site details revised
- Notable Start date: Aug 1, 2026 to Sep 2026
- Site contact updated
- Notable Eligibility criteria expanded, about 9 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with Clinical complete response (cCR)
Timeframe: approximately 36 weeks
Secondary (8)
Number of participants with pathologic complete response (pCR)
Number of participants who complete both chemoradiation and chemotherapy
Number of participants with local control
Number of participants with Disease free survival
Time to distant metastasis
Show 3 moreShow less
Overall survival
Number of participants with Local control
Disease free survival
Arms and interventions
Chemoradiation with consolidative chemotherapyExperimental
Participants will receive a standard course of chemoradiation followed by consolidative chemotherapy (FOLFOX regimen at the treating physician's discretion).
Drugs: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Sites
1 site in 1 country
- Duke University Medical CenterDurham, North Carolina, United States